Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.
about
Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapyEndocannabinoid system as a regulator of tumor cell malignancy - biological pathways and clinical significanceThe Tumorigenic Roles of the Cellular REDOX Regulatory SystemsCytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomicsInhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabineThe anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi)Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabineRationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.The molecular targets for the diagnosis and treatment of pancreatic cancer.Autophagic and apoptotic effects of HDAC inhibitors on cancer cellsGemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.Synergistic induction of apoptosis in A549 cells by dihydroartemisinin and gemcitabine.JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells.Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.Current knowledge on pancreatic cancer.Role of reactive oxygen species in the synergistic cytotoxicity of safingol-based combination regimens with conventional chemotherapeutics.Preclinical models of pancreatic ductal adenocarcinoma.Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.Current evidence for histone deacetylase inhibitors in pancreatic cancer.Synergistic antitumor activity of gemcitabine combined with triptolide in pancreatic cancer cells.The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistancePancreatic cancer: from molecular pathogenesis to targeted therapy.An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.Targeting histone deacetylases in pancreatic ductal adenocarcinoma.The sunset of somatic genetics and the dawn of epigenetics: a new frontier in pancreatic cancer researchBmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine.Reactive oxygen species in cancer.A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.Epigenetic silencing of tumor suppressor genes in pancreatic cancer.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Possible role of autophagy in the treatment of pancreatic cancer with histone deacetylase inhibitors.Histone deacetylase inhibitors and cell death.Cytotoxicity of gemcitabine enhanced by polyphenolics from Aronia melanocarpa in pancreatic cancer cell line AsPC-1.Targeting reactive oxygen species in development and progression of pancreatic cancer.HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells.Molecular determinants of the antitumor effects of trichostatin A in pancreatic cancer cells
P2860
Q24597964-AE853AE6-581B-4F04-9BD2-ABDB632BEAEBQ26739831-5DB4AC59-8C77-4D5B-85E6-CDD8D9CFDA10Q26774894-5E4D03B4-AE18-4DA0-98DB-6803D832EF90Q28252663-040065A1-A073-4F78-B012-32B91F050DE5Q28396251-1DE1A6B9-7761-4307-899A-5DF68D00453BQ28533258-25E36372-BDEF-4427-87CA-6D771C1D6C7CQ28534954-36FF6884-DA00-444A-9498-66D9943B6B5EQ34154791-5A99289E-026E-4957-B4EB-C6A888E06676Q34240470-CFB889B0-AB19-4A84-A0CC-5DA9CF4EA115Q34297701-76ECF707-83B8-4684-B3F7-108663552106Q34494019-44345A01-0B9A-4987-BF71-4681E21812FBQ35001459-5FB0384D-BFD0-40CB-AABB-C1C9740B86E4Q35064866-A548CC7C-D61D-43C9-B671-CF2C61F6CE01Q35066769-64EE78BB-9E87-4F98-9A53-E7F21EF419E9Q35238494-EA7AB8F4-CA30-4AC7-B167-2E31BDE68C9FQ35541771-38B201E6-F5F6-4252-A961-BC62D50AD152Q35971808-88E99415-CBBF-4C89-833B-CAED05A285E0Q36126626-ACE4129D-AB3D-48A0-925D-3A89A822ABE7Q36428208-B4F5FB63-2A26-49B4-923C-497460E4E46EQ36429978-92406EBF-E91C-44AE-810B-982E095EBB42Q36616790-CD05CF31-73A0-434C-BA67-202DB6913E3EQ36825562-5DF63F89-D9BB-4DED-9F14-152C8174AE3CQ36858120-E2D0D77E-D82A-4916-8AA6-7239933ACA87Q37144149-76335E88-0652-478A-88A0-749DBE9A28B6Q37175159-31B976BE-B218-4380-823D-D6BA65BA4E28Q37310587-46D2A987-1D86-4972-97ED-200168DB7190Q37362111-04FEEB27-0957-4A6D-B378-2182CC635BBEQ37392942-F540ED23-FA01-437F-B3E0-D550B6AF8BBEQ37431048-B4807493-B529-4EDE-95A4-D3439949D547Q37612692-E5C94800-185E-4BFD-8782-727C98303889Q37841191-C2B01E4B-6066-45EA-802C-2A40AFFAAC7AQ37994505-FF1EE34A-5FA3-4D31-831D-FC0ADD54AD68Q38166587-37E6C818-EC50-4812-B047-09D00A887AC7Q38217666-82FEBEEE-54D8-496C-8001-531481DD3B4BQ38955438-B6FBE7BD-E373-4D53-9092-2DC989DE0AEAQ39007517-8CC07F60-88A5-4757-BC06-01BCA535EADCQ39307665-B47FC426-C10C-4C02-B15C-09CA8E6E32B9Q39315907-A4737610-0E20-42F5-BA2F-F923F32D73F8Q39581269-AB6A3AC8-13D0-48A8-B75E-745E9F7333CBQ39710823-5D8A2538-F55C-455A-B555-CC7158790F76
P2860
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Synergistic inhibition of panc ...... richostatin A and gemcitabine.
@en
type
label
Synergistic inhibition of panc ...... richostatin A and gemcitabine.
@en
prefLabel
Synergistic inhibition of panc ...... richostatin A and gemcitabine.
@en
P2093
P50
P1476
Synergistic inhibition of panc ...... trichostatin A and gemcitabine
@en
P2093
Antonio Bonora
Chiara Costanzo
Mario Dandrea
Marta Palmieri
Paolo Piacentini
Stefania Beghelli
P304
P356
10.1016/J.BBAMCR.2007.05.002
P577
2007-05-22T00:00:00Z